From: Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors
Follow-up (month)
N (%)
6–12
2 (0.2%)
13–24
135 (12.5%)
25–36
198 (18.3%)
37–48
277 (25.6%)
49–60
155 (14.3%)
>  61
314 (29.0%)